Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Bayer looking for a "mid-size M&A transaction" in oncology

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 18, 2023 12:42pm

110 Views

Post# 35502466

RE:RE:RE:RE:RE:RE:RE:RE:Bayer looking for a "mid-size M&A transaction" in oncology

Big Phamra is facing a looming patent cliff which will primarily be addressed by acquistions of eary- late stage biotechnology companies.

Faced with this looming patent cliff and need to expand their oncology pipelines Bayer, for example, sees "good value" in moving on M&A transactions of between US$5 Billion to US$10 Billion, while Big Pharma's M&A "sweet-spot" is U$5 Billion to US415 Billion and US$1.5 Trillion in deal-making firepower.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing